๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Hepatitis C virus experimental model systems and antiviral drug research

โœ Scribed by Susan L. Uprichard

Book ID
107636107
Publisher
SP Wuhan Institute of Virology, CAS
Year
2010
Tongue
English
Weight
787 KB
Volume
25
Category
Article
ISSN
1674-0769

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Hepatitis C virus drug resistance and im
Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy
โœ Silvana Gaudieri; Andri Rauch; Katja Pfafferott; Eleanor Barnes; Wendy Cheng; Ge ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 368 KB

The efficacy of specifically targeted anti-viral therapy for hepatitis C virus (HCV) (STAT-C), including HCV protease and polymerase inhibitors, is limited by the presence of drugspecific viral resistance mutations within the targeted proteins. Genetic diversity within these viral proteins also evol

Efficacy of hepatitis B vaccine against
Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model
โœ Saleem Kamili; Vitini Sozzi; Geoff Thompson; Katie Campbell; Christopher M. Walk ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 579 KB

Hepatitis B virus (HBV) mutants resistant to treatment with nucleoside or nucleotide analogs and those with the ability to escape from HBV-neutralizing antibody have the potential to infect HBV-vaccinated individuals. To address this potential serious public health challenge, we tested the efficacy

Cost-effectiveness of hepatitis C virus
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations
โœ Natasha K. Martin; Peter Vickerman; Alec Miners; Graham R. Foster; Sharon J. Hut ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 291 KB ๐Ÿ‘ 1 views

Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a 1 ribavirin) has been shown to be costeffective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment